<DOC>
	<DOCNO>NCT00006682</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness vinorelbine combine docetaxel treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Vinorelbine Docetaxel Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate woman metastatic breast cancer treat vinorelbine docetaxel . II . Determine time disease progression , time treatment failure , response duration , survival patient population treat regimen . OUTLINE : This multicenter study . Patients receive vinorelbine IV day 1 8 , docetaxel IV 1 hour day 1 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow 1 month , every 1.5-3 month 1 year . PROJECTED ACCRUAL : Approximately 69 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV breast cancer Disease progression follow prior adjuvant chemotherapy ( disease progression treatment prior doxorubicin ) Bidimensionally measurable disease Prior radiotherapy allow disease completely outside radiation port histologic evidence measure area indicate malignancy radiation fibrosis No CNS metastases Brain metastasis previously treat radiotherapy surgical excision allow evidence residual metastasis brain CT MRI Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Premenopausal postmenopausal Performance status : ECOG 01 Life expectancy : Greater 16 week Hematopoietic : WBC least 2,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Renal : Not specify Cardiovascular : No symptomatic New York Heart Association class II great congestive heart failure No significant arrhythmia require drug therapy No myocardial infarction within past 6 month No uncontrolled cardiac disease unstable angina Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No preexisting clinically significant peripheral neuropathy ( prior neuropathy grade previously treat paclitaxel ) No unstable , preexist medical condition No serious active infection No underlying medical , psychological , familial , sociologic , geographic condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 7 day since prior hematopoietic growth factor ( filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa ) At least 7 day since prior platelet transfusion Chemotherapy : See Disease Characteristics No prior vinca alkaloid ( include vinorelbine docetaxel ) No concurrent antineoplastic agent Endocrine therapy : No concurrent anticancer hormonal agent Radiotherapy : See Disease Characteristics No concurrent palliative radiotherapy Surgery : See Disease Characteristics Other : No concurrent investigational drug device</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>